The INOVIO VOCERYQ FDA approval rests on a short, open-label study of 32 adults, so the science of how the product works, and how much weight the evidence can bear, deserve close reading. The FDA granted accelerated approval on 30 October 2026 to VOCERYQ, formerly INO-3107, to reduce the frequency of surgical papilloma removal in adults with recurrent respiratory papillomatosis (RRP), a rare airway disease caused mainly by HPV types 6 and 11. This article explains the immunology, the electroporation delivery, the trial results with their uncertainty, the safety warnings and the confirmatory evidence still to come.
INOVIO VOCERYQ FDA approval: the evidence in brief
- Design: RRP-001, a Phase 1/2 single-arm study in 32 adults, all of whom completed it.
- Efficacy population: 26 patients with at least 3 excisions in the prior 12 months (median 4.5, range 3 to 8).
- Primary signal: 7 of 26 (27%, 95% confidence interval 12% to 48%) needed no surgery over 12 months of follow-up.
- Regimen: surgical debulking, then a 9-week course given by intramuscular injection with electroporation.
- Regulatory status: accelerated approval, with a confirmatory study required.
The immunology behind the INOVIO VOCERYQ FDA approval
HPV 6 and 11 infect the lining of the airway and drive papilloma growth. The immune system does not always clear the infection, which is one reason lesions return after surgery. VOCERYQ is built to teach T cells to recognise HPV-6 and HPV-11 proteins. According to coverage of the label, it contains one plasmid encoding HPV-6 and HPV-11 antigens and another encoding interleukin-12, a signalling protein that supports T-cell responses. INOVIO has reported activated CD4 and CD8 T cells with lytic potential, still present at Week 52. Laboratory immune measures show the product does something, but they are not proof of clinical benefit.
Electroporation and the INOVIO VOCERYQ FDA approval
Naked DNA is taken up poorly by muscle cells. The CELLECTRA 5PSP device delivers short electrical pulses at the injection site that open pores in cell membranes, letting plasmids enter. The label therefore warns of muscle contractions, transient bleeding, anxiety, vasovagal reactions and brief changes in creatine phosphokinase, and advises against use on the same side as an implanted cardioverter-defibrillator or pacemaker, at sites with metal implants or where the skin is abnormal. Patients should be observed for at least 30 minutes after treatment. Device and drug were approved together.
Reading the trial data in the INOVIO VOCERYQ FDA approval
A 27% complete-response rate with a confidence interval of 12% to 48% shows that the true rate could plausibly be anywhere from about one in eight to nearly one in two. The study had no control arm, so it cannot separate drug effect from the natural variation of RRP, which can wax and wane. The company argues that complete freedom from surgery is not expected in the untreated natural history of the disease. In the broader 32-patient group, earlier reports said 72% had a 50% to 100% reduction in surgeries in year one, and a follow-up of 28 participants reported 86% in the second year, with half needing no surgery. Those follow-up numbers come from company materials and a retrospective study. By our own calculation, six of the 32 patients fall outside the 26-patient efficacy population because they had fewer than 3 excisions.
Safety in the INOVIO VOCERYQ FDA approval
The most common adverse reactions were injection site reactions, headache, fatigue, hypertension, nausea and dizziness. Most treatment-related reactions were grade 1 or 2 and transient, and no common adverse events were grade 4 or 5. With 32 participants, rare events cannot be excluded, which is one reason post-marketing monitoring matters. Prescribing information is the authoritative source for clinicians, and the FDA approval explainer is on its accelerated approval page.
The confirmatory question after the INOVIO VOCERYQ FDA approval
Surgery frequency is an intermediate endpoint that the FDA considers reasonably likely to predict benefit. The confirmatory study must show that benefit more directly. INOVIO must submit a draft protocol by the end of 2026 and expects alignment on the final protocol by mid-2027. Because RRP is rare, enrolling a controlled trial is difficult, and the design, whether randomised or externally controlled, has not been disclosed. The disease background is described by the CDC.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Plasmid DNA Manufacturing Market report values the global market at USD 1.9 billion in 2023 and projects USD 10.5 billion by 2032, a CAGR of 20.9%, with clinical therapeutics holding around 54% and GMP-grade plasmid generating more than USD 1.6 billion in 2023. The page contains inconsistent figures and an old update date, so it is directional only. It describes manufacturing supply and not demand for VOCERYQ. See our Bio Technology section.
Timeline of the INOVIO VOCERYQ FDA approval
- 29 December 2025: BLA accepted for standard review.
- 30 October 2026: accelerated approval.
- End of 2026: draft confirmatory protocol due.
- Mid-2027: final protocol alignment expected.
General background: DNA immunotherapy versus viral-vector approaches
Plasmid DNA and viral vectors both deliver genetic instructions. Viral vectors infect cells efficiently but can trigger immunity against the vector, which may limit repeat dosing, while plasmids avoid that but need a delivery aid such as electroporation. Which approach is better for RRP is not answered by the available data.
Our analysis of the INOVIO VOCERYQ FDA approval
In our assessment, the INOVIO VOCERYQ FDA approval is credible as a signal of activity and acceptable safety but remains provisional evidence. The single-arm design and the wide confidence interval are the main limits, and the confirmatory study will decide.
What is not disclosed about the INOVIO VOCERYQ FDA approval
- Confirmatory study design.
- Long-term durability beyond two years in a controlled setting.
- Comparative data against other RRP immunotherapies.
Risks and caveats
This article relies on the company announcement and press coverage of the label and does not include the full prescribing information. It is news reporting and not medical advice.
What to watch next
- Confirmatory protocol.
- Real-world surgery counts.
- Post-marketing safety.
FAQ
How does VOCERYQ work?
It delivers plasmids that train T cells against HPV-6 and HPV-11.
Does it cure RRP?
No, it aims to reduce surgeries.
Is the evidence strong?
It is early: 32 patients, no control group.
How we reported this: we relied on the INOVIO announcement and press coverage of the label, public pages from the FDA and CDC, and the Acumen Research and Consulting report cited above. Our calculation is labelled. Last updated 2 November 2026. This is news reporting and not advice.
